컴벌랜드 파마슈티컬스(CPIX) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

CPIX

Cumberland Pharmaceuticals Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$7.03

+0.42 ▲ +6.35%

컴벌랜드 파마슈티컬스(CPIX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$105M

스몰캡

P/E

배당수익률

없음

52주 위치

83%

저점 +280% · 고점 -13%

애널리스트

적극 매수

C+

Fundamental health

vs. Drug Manufacturers - Specialty & Generic· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 58%

밸류에이션

Top 23%

재무 안정

Top 70%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.49	Insider Own ⓘ	41.6%	Shs Outstand ⓘ	15.0M	Perf Week ⓘ	-3.7%
Market Cap ⓘ	0.11B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	8.8M	Perf Month ⓘ	17.95%
Enterprise Value ⓘ	0.10B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	18.43%	Short Float ⓘ	4.26%	Perf Quarter ⓘ	73.15%
Income ⓘ	-0.01B	P/S ⓘ	2.51	EPS this Y ⓘ	-	Inst Trans ⓘ	-4.93%	Short Ratio ⓘ	2.76	Perf Half Y ⓘ	78.88%
Sales ⓘ	0.04B	P/B ⓘ	4.87	EPS next 5Y ⓘ	-	ROA ⓘ	-10.48%	Short Interest ⓘ	0.37M	Perf YTD ⓘ	76.63%
Book/sh ⓘ	1.44	P/C ⓘ	9.57	EPS past 3/5Y ⓘ	20.68% 2.82%	ROE ⓘ	-29.36%	52W High ⓘ	-13.1% ($8.09)	Perf Year ⓘ	100%
Cash/sh ⓘ	0.73	P/FCF ⓘ	76.89	Sales past 3/5Y ⓘ	1.95% 3.52%	ROIC ⓘ	-23.65%	52W Low ⓘ	280% ($1.85)	Perf 3Y ⓘ	359.48%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-106.57%	Gross Margin ⓘ	72.42%	Volatility(W/M) ⓘ	14.05% 11.15%	Perf 5Y ⓘ	107.37%
Dividend TTM ⓘ	-	EV/Sales ⓘ	2.48	Sales Y/Y TTM ⓘ	2.08%	Oper. Margin ⓘ	-16.75%	ATR (14) ⓘ	0.72	Perf 10Y ⓘ	49.89%
Dividend Ex-Date ⓘ	2026/8/3	Quick Ratio ⓘ	0.79	EPS Q/Q ⓘ	-366.87%	Profit Margin ⓘ	-17.6%	RSI (14) ⓘ	54.25	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	0.95	Sales Q/Q ⓘ	-22.04%	SMA20 ⓘ	3.23% ($6.81)	Beta ⓘ	0.09	Target Price ⓘ	$9.75
Payout ⓘ	-	Debt/Eq ⓘ	0.47	Earnings ⓘ	2026/5/5	SMA50 ⓘ	14.27% ($6.15)	Rel Volume ⓘ	0.54	Prev Close ⓘ	$6.61
Employees ⓘ	93	LT Debt/Eq ⓘ	0.44	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	69.68% ($4.14)	Avg Volume(3M) ⓘ	0.13M	Price ⓘ	$7.03
IPO ⓘ	2009/8/11	Option/Short ⓘ	Yes/Yes			Trades ⓘ	571	Volume ⓘ	72,193	Change ⓘ	6.35%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12

25.3

25.6

25.9

25.12

26.3

Revenue Net income 최근 분기: 매출 $9M (YoY -22%) · 순이익 $-3M (YoY -362%)

📊 Cumberland Pharmaceuticals Inc (CPIX) Investment Analysis

What kind of company is Cumberland Pharmaceuticals Inc?

컴벌랜드 파마슈티컬스(CPIX) 방어주

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

Cumberland Pharmaceuticals is a specialty pharmaceutical company headquartered in Nashville, Tennessee, USA. It acquires, develops, and markets branded prescription drugs in the areas of hospital acute care, gastroenterology, rheumatology, and oncology, supplying approved products through its hospital, field, and oncology sales organizations across the United States. Recently, the company has been shifting its focus toward a rare disease pipeline alongside the reshaping of its commercial portfolio.

Learn more about Cumberland Pharmaceuticals Inc →

Market Cap

$0.1B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4517

Employees93people

IPO2009/08/11

Current Price$7.03 ≈ 9,631원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date D-6

8월 3일 (월)

지급 7월 31일 (금)

💡 배당을 받으려면 8월 2일까지 매수하는게 좋습니다

📜 Recent events

🎯 Ex-div 2026년 7월 23일 (목)

🔔 Earnings release 2026년 5월 5일 (화) · 장 마감 후

🔔 Earnings release 2026년 3월 3일 (화) · 장 마감 후

Is it profitable?

Profitability weak

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-16.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-17.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

72.4%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Top tier

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-29.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-10.5%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-23.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.47

✓ Healthy debt

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

0.95

✓ 부진

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.79

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$9.75

현재가 대비 +38.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+20.7%

평균

My positionMid-range

Low range Average High range

방어주 초소형주 Median 30.0% · Bottom 42%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+2.8%

평균

My positionMid-range

Low range Average High range

방어주 초소형주 Median 16.4% · Bottom 36%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+3.5%

양호

My positionMid-range

Low range Average High range

방어주 초소형주 Median 2.1% · Top 45%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-22.0%

평균

My positionMid-range

Low range Average High range

방어주 초소형주 Median -4.5% · Bottom 35%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 39%p over 5 years

CPIX +107.4% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+39.0%p

well ahead of the market

vs Health Care (XLV)

+82.9%p

well ahead of the sector average

1-year basis

vs S&P 500

+84.0%p

well ahead of the market

vs Health Care (XLV)

+80.3%p

well ahead of the sector average

Rank among peers

5-year return Top among peers Based on 28 peers

1-year return Top among peers Based on 36 peers

Current position within 52-week range

Low (-280.0%p) High (-13.1%p)

Current price is 280.0% above the 52-week low and 13.1% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-43.1%

Annualized volatility

88.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $7.03 above the midline ($6.81). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.318 · Signal 0.362 · Hist -0.044. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 54.2 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 54.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Assets·Vs. Cash Flow, In line with peers on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Pricey

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Pricey

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

4.87x

✓ Very pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 0.78x · Bottom 6% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

2.51x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

76.89x

✓ Pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Bottom 16% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$9.75 vs. current price +38.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership flow shows some pressure

Institutional net selling -4.9% · Short interest light 4.3% · Short interest up +2.2pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-4.9%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 18.4%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 41.6%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 40.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

4.3%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +2.2%p increase

Short interest days to cover

2.8 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 15.0M주

Float (tradable shares) 8.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding CPIX

ETFs with the highest weightings · 8 total shown

IWC

iShares Micro-Cap ETF

0.01%

$1.4B

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

DFAS

Dimensional U.S. Small Cap ETF

0.00%

$15.2B

DFAT

Dimensional U.S. Targeted Value ETF

0.00%

$14.5B

DFSU

Dimensional US Sustainability Core 1 ETF

0.00%

$2.2B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
CPIX This Stock	$105.3M	-	4.9 ▼	-29.36% ▲	-	+6.3%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 컴벌랜드 파마슈티컬스(CPIX)?

컴벌랜드 파마슈티컬스(CPIX) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of CPIX?

The market cap of CPIX is approximately $105M, ranking 4,517 within its sector.

What is the 52-week high and low for CPIX?

CPIX has recorded a 52-week high of $8.09 and a low of $1.85.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.